At the request of Investment Industry Regulatory Organization of Canada ("IIROC"), Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV) (the "Company") wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its common shares. As announced on December 11, 2019, the Company is engaged in a process to explore strategic options to maximize stakeholder value which is ongoing. Correvio has not set a timetable for completion of this review process and the Company does not intend to comment further unless or until the Board of Directors has approved a definitive course of action, the review process is concluded, or it is determined that other disclosure is appropriate.
VANCOUVER , May 6, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, released a report (the "Glass Lewis Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.
Benzinga Pro's Stocks To Watch For Tuesday * iShares China Large-Cap ETF (FXI) \- The most-active ETF reflecting price action in the broader Chinese markets, the FXI was up more than 3% in pre-market action. A Global Times report suggested the last patient was discharged from the Wuchang makeshift hospital in Wuhan on Tuesday. Additionally, Chinese President Xi declared victory over the coronavirus in the city of Wuhan. US futures were up about 4% and hit a limit up circuit breaker -- the opposite of what happened in pre-market action Monday morning. * Tesla (TSLA) \- The stock was up about 9% to over the $650 level. A report suggested Tesla plans to increase production capacity for certain parts at its Shanghai factory. * Occidental Petroleum (OXY) \- One of the hardest hit oil & gas stocks Monday amid the massive drop in crude oil prices, Occidental shares rebounded Tuesday. After the stock fell more than 50% on Monday, shares were up 23% Tuesday morning. More than 103 million shares were traded on Monday, compared to the stock's average daily volume of just 13 million shares. * Correvio Pharma (CORV) \- Shares were up 30% following news of a partnership with Hong Kong Teson Pharma Limited for an exclusive agreement for the commercialization of Aggrastat® for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. * Cloudera (CLDR) \- Will report Q4 results after the market close on Tuesday. Analysts expect a loss of about $0.03/share on sales of about $202 million.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 9, 2020: XOM, GLD, BA, TSLA, SPEX * Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 18, 2020: AAPL, WMT, TSLA, FLR, SPWR * Benzinga Pro's Top 5 Stocks To Watch For Fri., Feb. 14, 2020: TSLA, ROKU, CRON, YELP, AMD(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Correvio Pharma Corp. (NasdaqGS: CORV) to ADVANZ PHARMA Corp. Limited. Under the terms of the proposed transaction, shareholders of Correvio will receive only $0.42 in cash for each share of Correvio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, March 24, 2020 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders..
VANCOUVER , May 15, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced the results of voting on matters considered at its annual general and special meeting (the "Meeting") of Correvio shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") which took place in a virtual format earlier today. At the Meeting, Securityholders were asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA").
Correvio (CORV) delivered earnings and revenue surprises of 23.08% and -1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, CA / ACCESSWIRE / February 10, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced its entry into an arrangement agreement ("Arrangement Agreement") dated March 15, 2020, for ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA", TSX:ADVZ) to acquire all of the issued and outstanding shares of Correvio. The acquisition, which will be executed through ADVANZ PHARMA's wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), is expected to have a total purchase price of approximately US$76 million, which includes the repayment of certain Correvio indebtedness, pursuant to a plan of arrangement under the Canada Business Corporations Act (the "Arrangement").
Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VANCOUVER , April 8, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained an interim order from the Supreme Court of British Columbia (the "Court") authorizing the holding of an annual general and special meeting (the "Meeting") of the Securityholders (as defined below) and matters relating to the conduct of the Meeting. At the Meeting, shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") will be asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA").
Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, and Hong Kong Teson Pharma Limited (Teson), a privately-held pharmaceutical company, today announced that Correvio International Sàrl, a wholly owned subsidiary of Correvio, and Teson have entered into an exclusive agreement for the commercialization of Aggrastat® (tirofiban hydrochloride). The agreement covers the territories of mainland China (excluding Taiwan and Hong Kong) and Macau. Aggrastat® is Correvio's marketed asset for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
Correvio Pharma Corp.'s (TSE:CORV): Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing...
VANCOUVER , May 21, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") pursuant to which ADVANZ PHARMA, through its wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), has agreed to acquire all of the issued and outstanding shares of Correvio for a total purchase price of approximately US$76 million , which includes the repayment of certain Correvio indebtedness, as described in Correvio's information circular dated April 16, 2020 . The Arrangement was previously approved by Correvio securityholders at the annual general and special meeting of securityholders held on May 15, 2020 .
Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:
Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for the full year ended December 31, 2019 and commented on recent accomplishments and plans.
Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has postponed the reporting of its financial statements and management discussion and analysis (the "2020 Disclosure") in respect of the first quarter ended March 31, 2020 beyond the previous expected date of May 15, 2020. The Company now expects to release its 2020 Disclosure on or before June 29, 2020, subject to the Company ceasing to be a reporting issuer prior to the filing deadline as a result of the Proposed Arrangement (as defined below).
Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - TTPH, CORV NEW YORK, NY / ACCESSWIRE / March 16, 2020 / Halper Sadeh LLP, a global investor rights law ...
Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, released a report (the "ISS Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.